U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C29H35F3N2O3
Molecular Weight 516.5961
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of SIPONIMOD

SMILES

CCc1cc(ccc1CN2CC(C2)C(=O)O)/C(=N/OCc3ccc(C4CCCCC4)c(c3)C(F)(F)F)/C

InChI

InChIKey=KIHYPELVXPAIDH-HNSNBQBZSA-N
InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+

HIDE SMILES / InChI
Siponimod (BAF312) is a dual agonist at the sphingosine-1 phosphate receptors, S1PR1 and S1PR5. The S1P receptor is commonly found on the surface of specific cells residing in the central nervous system (CNS), that are responsible for causing CNS damage that drives loss of function in secondary progressive multiple sclerosis (SPMS). Siponimod (BAF312) enters the brain and by binding to these specific receptors, may prevent the activation of these harmful cells, helping to reduce the loss of physical and cognitive function associated with SPMS.

Originator

Curator's Comment:: # Novartis Pharma AG

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.39 nM [EC50]
0.98 nM [EC50]
750.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SIPONIMOD

Approved Use

Unknown
Palliative
SIPONIMOD

Approved Use

Unknown
Palliative
SIPONIMOD

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
30.4 ng/mL
2 mg 1 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SIPONIMOD plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
558 ng × h/mL
2 mg 1 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SIPONIMOD plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
30 h
2 mg 1 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SIPONIMOD plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1 mg single, intravenous
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
healthy, 18-50 years
n = 17
Health Status: healthy
Age Group: 18-50 years
Population Size: 17
Sources:
Other AEs: Feeling hot, Dizziness...
Other AEs:
Feeling hot (5.9%)
Dizziness (5.9%)
Headache (5.9%)
Presyncope (5.9%)
Blurred vision (5.9%)
Dry lips (5.9%)
Nasopharyngitis (5.9%)
Vaginal discharge (5.9%)
Sources:
2 mg 1 times / day steady, oral
Recommended
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources:
Disc. AE: Headache, Transaminases increased...
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources:
Disc. AE: Hypertension...
AEs leading to
discontinuation/dose reduction:
Hypertension (10%)
Sources:
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources: Page: p. 109
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources: Page: p. 109
Disc. AE: Macular edema, ALT increased...
AEs leading to
discontinuation/dose reduction:
Macular edema (1%)
ALT increased (0.5%)
Bradycardia (0.3%)
GGT increased (0.3%)
AST increased (0.3%)
Depression (0.3%)
Dizziness (0.3%)
Fatigue (0.3%)
Pulmonary function test decreased (0.3%)
Angina pectoris (0.2%)
Edema peripheral (0.2%)
Seminoma (0.2%)
Uveitis (0.2%)
Lymphopenia (0.1%)
Urinary tract infection (0.1%)
Sources: Page: p. 109
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p. 38
healthy, adult
Health Status: healthy
Age Group: adult
Sources: Page: p. 38
Other AEs: Headache, Dizziness...
Other AEs:
Headache (20.8%)
Dizziness (5.7%)
Nausea (4.2%)
Sources: Page: p. 38
75 mg single, oral
Highest studied dose
Dose: 75 mg
Route: oral
Route: single
Dose: 75 mg
Sources: Page: p. 38
healthy, adult
Health Status: healthy
Age Group: adult
Sources: Page: p. 38
Other AEs: Headache, Dizziness...
Other AEs:
Headache (32%)
Dizziness (12.1%)
Nausea (5.5%)
Sources: Page: p. 38
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p. 109
unhealthy, adult
n = 50
Health Status: unhealthy
Age Group: adult
Population Size: 50
Sources: Page: p. 109
Disc. AE: Macular edema, ALT increased...
AEs leading to
discontinuation/dose reduction:
Macular edema (2%)
ALT increased (2%)
ALT increased (2%)
AST increased (2%)
Dizziness (4%)
Edema peripheral (2%)
Headache (2%)
Lymphopenia (4%)
Sources: Page: p. 109
AEs

AEs

AESignificanceDosePopulation
Blurred vision 5.9%
1 mg single, intravenous
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
healthy, 18-50 years
n = 17
Health Status: healthy
Age Group: 18-50 years
Population Size: 17
Sources:
Dizziness 5.9%
1 mg single, intravenous
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
healthy, 18-50 years
n = 17
Health Status: healthy
Age Group: 18-50 years
Population Size: 17
Sources:
Dry lips 5.9%
1 mg single, intravenous
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
healthy, 18-50 years
n = 17
Health Status: healthy
Age Group: 18-50 years
Population Size: 17
Sources:
Feeling hot 5.9%
1 mg single, intravenous
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
healthy, 18-50 years
n = 17
Health Status: healthy
Age Group: 18-50 years
Population Size: 17
Sources:
Headache 5.9%
1 mg single, intravenous
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
healthy, 18-50 years
n = 17
Health Status: healthy
Age Group: 18-50 years
Population Size: 17
Sources:
Nasopharyngitis 5.9%
1 mg single, intravenous
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
healthy, 18-50 years
n = 17
Health Status: healthy
Age Group: 18-50 years
Population Size: 17
Sources:
Presyncope 5.9%
1 mg single, intravenous
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
healthy, 18-50 years
n = 17
Health Status: healthy
Age Group: 18-50 years
Population Size: 17
Sources:
Vaginal discharge 5.9%
1 mg single, intravenous
Dose: 1 mg
Route: intravenous
Route: single
Dose: 1 mg
Sources:
healthy, 18-50 years
n = 17
Health Status: healthy
Age Group: 18-50 years
Population Size: 17
Sources:
Headache 0.1%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources:
Transaminases increased 0.9%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources:
Hypertension 10%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources:
Lymphopenia 0.1%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources: Page: p. 109
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources: Page: p. 109
Urinary tract infection 0.1%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources: Page: p. 109
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources: Page: p. 109
Angina pectoris 0.2%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources: Page: p. 109
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources: Page: p. 109
Edema peripheral 0.2%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources: Page: p. 109
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources: Page: p. 109
Seminoma 0.2%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources: Page: p. 109
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources: Page: p. 109
Uveitis 0.2%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources: Page: p. 109
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources: Page: p. 109
AST increased 0.3%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources: Page: p. 109
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources: Page: p. 109
Bradycardia 0.3%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources: Page: p. 109
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources: Page: p. 109
Depression 0.3%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources: Page: p. 109
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources: Page: p. 109
Dizziness 0.3%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources: Page: p. 109
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources: Page: p. 109
Fatigue 0.3%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources: Page: p. 109
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources: Page: p. 109
GGT increased 0.3%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources: Page: p. 109
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources: Page: p. 109
Pulmonary function test decreased 0.3%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources: Page: p. 109
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources: Page: p. 109
ALT increased 0.5%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources: Page: p. 109
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources: Page: p. 109
Macular edema 1%
Disc. AE
2 mg 1 times / day steady, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources: Page: p. 109
unhealthy, 49.0 years
n = 1148
Health Status: unhealthy
Condition: secondary progressive multiple sclerosis
Age Group: 49.0 years
Sex: M+F
Population Size: 1148
Sources: Page: p. 109
Headache 20.8%
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p. 38
healthy, adult
Health Status: healthy
Age Group: adult
Sources: Page: p. 38
Nausea 4.2%
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p. 38
healthy, adult
Health Status: healthy
Age Group: adult
Sources: Page: p. 38
Dizziness 5.7%
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p. 38
healthy, adult
Health Status: healthy
Age Group: adult
Sources: Page: p. 38
Dizziness 12.1%
75 mg single, oral
Highest studied dose
Dose: 75 mg
Route: oral
Route: single
Dose: 75 mg
Sources: Page: p. 38
healthy, adult
Health Status: healthy
Age Group: adult
Sources: Page: p. 38
Headache 32%
75 mg single, oral
Highest studied dose
Dose: 75 mg
Route: oral
Route: single
Dose: 75 mg
Sources: Page: p. 38
healthy, adult
Health Status: healthy
Age Group: adult
Sources: Page: p. 38
Nausea 5.5%
75 mg single, oral
Highest studied dose
Dose: 75 mg
Route: oral
Route: single
Dose: 75 mg
Sources: Page: p. 38
healthy, adult
Health Status: healthy
Age Group: adult
Sources: Page: p. 38
ALT increased 2%
Disc. AE
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p. 109
unhealthy, adult
n = 50
Health Status: unhealthy
Age Group: adult
Population Size: 50
Sources: Page: p. 109
ALT increased 2%
Disc. AE
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p. 109
unhealthy, adult
n = 50
Health Status: unhealthy
Age Group: adult
Population Size: 50
Sources: Page: p. 109
AST increased 2%
Disc. AE
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p. 109
unhealthy, adult
n = 50
Health Status: unhealthy
Age Group: adult
Population Size: 50
Sources: Page: p. 109
Edema peripheral 2%
Disc. AE
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p. 109
unhealthy, adult
n = 50
Health Status: unhealthy
Age Group: adult
Population Size: 50
Sources: Page: p. 109
Headache 2%
Disc. AE
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p. 109
unhealthy, adult
n = 50
Health Status: unhealthy
Age Group: adult
Population Size: 50
Sources: Page: p. 109
Macular edema 2%
Disc. AE
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p. 109
unhealthy, adult
n = 50
Health Status: unhealthy
Age Group: adult
Population Size: 50
Sources: Page: p. 109
Dizziness 4%
Disc. AE
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p. 109
unhealthy, adult
n = 50
Health Status: unhealthy
Age Group: adult
Population Size: 50
Sources: Page: p. 109
Lymphopenia 4%
Disc. AE
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p. 109
unhealthy, adult
n = 50
Health Status: unhealthy
Age Group: adult
Population Size: 50
Sources: Page: p. 109
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
unlikely [IC50 >100 uM]
unlikely [IC50 >100 uM]
unlikely [IC50 >200 uM]
unlikely [IC50 >200 uM]
unlikely [IC50 >200 uM]
unlikely [IC50 >200 uM]
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
weak [IC50 100 uM]
weak [IC50 230 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
yes
yes (co-administration study)
Comment: administered with fluconazole (moderate CYP2C9 and CYP3A4 dual inhibitor): increased siponimod’s Cmax by 10% and the AUC 2-fold; administered with rifampin (strong CYP3A4 and moderate CYP2C9 dual inducer) decreased siponimod AUCtau,ss and Cmax,ss by 57% and 45%, respectively.
Page: 16.0
yes
yes (pharmacogenomic study)
Comment: administered with fluconazole (moderate CYP2C9 and CYP3A4 dual inhibitor): increased siponimod’s Cmax by 10% and the AUC 2-fold; administered with rifampin (strong CYP3A4 and moderate CYP2C9 dual inducer) decreased siponimod AUCtau,ss and Cmax,ss by 57% and 45%, respectively.
Page: 16.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
2012
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.
2012 Nov
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
2013 Apr 1
Modulators of the Sphingosine 1-phosphate receptor 1.
2013 Dec 1
Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator.
2013 Mar 14
Sphingosine 1-phosphate receptor modulators in multiple sclerosis.
2015 Jul
Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.
2016 Aug 26
The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures.
2016 Feb 8
Patents

Sample Use Guides

Patients received 2 mg once daily siponimod (following initial dose titration starting at 0.25 mg).
Route of Administration: Oral
The selectivity of siponimod (BAF312) for receptor subtypes S1P1 and S1P5, sparing activity on the S1P2, S1P3 and S1P4 receptors, was demonstrated by measuring agonist efficacy in the GTPγ[35S] binding assay. The half-maximal effective concentration (EC50) values were in the sub-nanomolar range for S1P1 (0.39 ± 0.07 nM) and S1P5 (0.98 ± 0.43 nM) receptors, with Emax levels of approximately 100% (full agonist).
Name Type Language
SIPONIMOD
INN   WHO-DD  
USAN   INN  
Official Name English
1-((4-((1E)-1-(((4-CYCLOHEXYL- 3-(TRIFLUOROMETHYL)PHENYL)METHOXY)IMINO)ETHYL)- 2-ETHYLPHENYL)METHYL)AZETIDINE-3-CARBOXYLIC ACID
Systematic Name English
3-AZETIDINECARBOXYLIC ACID, 1-((4-((1E)-1-(((4-CYCLOHEXYL-3-(TRIFLUOROMETHYL)PHENYL)METHOXY)IMINO)ETHYL)-2-ETHYLPHENYL)METHYL)-
Systematic Name English
SIPONIMOD [INN]
Common Name English
NVP-BAF312-NX
Code English
BAF312
Code English
BAF-312
Code English
SIPONIMOD [WHO-DD]
Common Name English
SIPONIMOD [USAN]
Common Name English
SIPONIMOD [MI]
Common Name English
MAYZENT
Brand Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 437614
Created by admin on Sat Jun 26 09:42:19 UTC 2021 , Edited by admin on Sat Jun 26 09:42:19 UTC 2021
FDA ORPHAN DRUG 413413
Created by admin on Sat Jun 26 09:42:19 UTC 2021 , Edited by admin on Sat Jun 26 09:42:19 UTC 2021
NCI_THESAURUS C308
Created by admin on Sat Jun 26 09:42:19 UTC 2021 , Edited by admin on Sat Jun 26 09:42:19 UTC 2021
EU-Orphan Drug EU/3/14/1370
Created by admin on Sat Jun 26 09:42:19 UTC 2021 , Edited by admin on Sat Jun 26 09:42:19 UTC 2021
Code System Code Type Description
LACTMED
Siponimod
Created by admin on Sat Jun 26 09:42:19 UTC 2021 , Edited by admin on Sat Jun 26 09:42:19 UTC 2021
PRIMARY
INN
9491
Created by admin on Sat Jun 26 09:42:19 UTC 2021 , Edited by admin on Sat Jun 26 09:42:19 UTC 2021
PRIMARY
RXCUI
2121085
Created by admin on Sat Jun 26 09:42:19 UTC 2021 , Edited by admin on Sat Jun 26 09:42:19 UTC 2021
PRIMARY
CAS
1230487-00-9
Created by admin on Sat Jun 26 09:42:19 UTC 2021 , Edited by admin on Sat Jun 26 09:42:19 UTC 2021
PRIMARY
MERCK INDEX
M12146
Created by admin on Sat Jun 26 09:42:19 UTC 2021 , Edited by admin on Sat Jun 26 09:42:19 UTC 2021
PRIMARY
PUBCHEM
44599207
Created by admin on Sat Jun 26 09:42:19 UTC 2021 , Edited by admin on Sat Jun 26 09:42:19 UTC 2021
PRIMARY
EVMPD
SUB177510
Created by admin on Sat Jun 26 09:42:19 UTC 2021 , Edited by admin on Sat Jun 26 09:42:19 UTC 2021
PRIMARY
DRUG CENTRAL
5326
Created by admin on Sat Jun 26 09:42:19 UTC 2021 , Edited by admin on Sat Jun 26 09:42:19 UTC 2021
PRIMARY
DRUG BANK
DB12371
Created by admin on Sat Jun 26 09:42:19 UTC 2021 , Edited by admin on Sat Jun 26 09:42:19 UTC 2021
PRIMARY
NCI_THESAURUS
C152368
Created by admin on Sat Jun 26 09:42:19 UTC 2021 , Edited by admin on Sat Jun 26 09:42:19 UTC 2021
PRIMARY
ChEMBL
CHEMBL2336071
Created by admin on Sat Jun 26 09:42:19 UTC 2021 , Edited by admin on Sat Jun 26 09:42:19 UTC 2021
PRIMARY
FDA UNII
RR6P8L282I
Created by admin on Sat Jun 26 09:42:19 UTC 2021 , Edited by admin on Sat Jun 26 09:42:19 UTC 2021
PRIMARY